253 - POST-CANCER THERAPY CARDIOVASCULAR SURVEILLANCE AND MANAGMENT - THE CARDIOLOGIST'S ROLE, WHAT SHOULD WE DO AND WHEN?

Friday, October 24, 2025

3:15pm - 4:15pm ET

Room:207

Target Audience: Community cardiologists, Academic cardiovascular health professionals and researchers, Trainee (clinical)

Co-Chair(s)

Fernando Rivera-Theurel, MD, MSc

Assistant Professor, Clinitian Investigator
University Of Toronto
University of Toronto
IS

Igal Sebag, MD, FRCPC, FACC, FASE (he/him/his)

President
Canadian Society of Echocardiography
McGill University

Panelist(s)

MD

Margot Davis, MD SM FRCPC FCCS (she/her/hers)

Cardiologist
University of British Columbia
University of British Columbia
Ahmad Didi, M.D (he/him/his)

Assistant professor of Medicine
University of Manitoba
University of Manitoba
ME

Malak El-Rayes, MD FRCP

Cardiologist, CSSS de Laval
CCON
University of Montreal
DL

Darryl Leong, MBBS (Hons) MPH M.Biostat PhD FRACP FESC

Director of the Cardio-Oncology Program at Hamilton Health Sciences
McMaster University and Hamilton Health Sciences
McMaster University
Guillaume St-Pierre, MD, FRCPC (he/him/his)

Cardiologue et cardio-oncologue chez CISSS de Chaudière-Appalaches
Laval University

Presenter(s)

EG

Enrique Gonzalez, M.D.
Cristina Pop, MD (she/her/hers)

Medical Resident
McGill University
McGill University
Jonathan Sen, MBBS, PhD, FRACP

Cardio-oncology Fellow
University Health Network

Early Career(s)

Christopher Yu, MBBS, PhD

Cardiologist
University Health Network
University of Toronto

Trainee(s)

EG

Enrique Gonzalez, M.D.
Cristina Pop, MD (she/her/hers)

Medical Resident
McGill University
McGill University
Jonathan Sen, MBBS, PhD, FRACP

Cardio-oncology Fellow
University Health Network

Moderator(s)

Fernando Rivera-Theurel, MD, MSc

Assistant Professor, Clinitian Investigator
University Of Toronto
University of Toronto
DT

Dinesh Thavendiranathan, MD, SM, FRCPC, FASE

Cardiologist
CCON
University of Toronto

Planning Committee Member(s)

Husam Abdel-Qadir, MD, PhD

Associate Professor, Department of Medicine and Institute of Health Policy Management and Evaluation
University of Toronto
Women's College Hospital, University Health Network, University of Toronto
CB

Christine Brezden-Masley, MD

Medical Director, Cancer Program
Mount Sinai Hospital
University of Toronto
MN

Michelle Nadler, M.D., MsC

Assistant Professor, University of Toronto
CCON
Christopher Yu, MBBS, PhD

Cardiologist
University Health Network
University of Toronto
AZ

Amna Zafar, M.D., F.R.C.P.C.

Cardiologist
Mount Sinai Hospital

Workshop Description: This workshop will involve a case-based discussion regarding post-cancer therapy surveillance and management of patients with breast, prostate cancer, and lung cancer. These cancers are chosen as breast and prostate cancer are the most common cancers in women and men, respectively, and lung cancer is the most common cancer with pre-existing CVD and at highest risk of new diagnosis of CVD during/post therapy. A 7-minute case presentation will be followed by an 11-minute discussion led by a panel of experts, with interaction with the audience. The session will focus on who needs surveillance, who should perform surveillance, strategies targeted for therapies, and a multidisciplinary approach to managing cardiovascular disease. The session will close with the key take-home points for the audience.

Learning Objectives:

At the end of this session participants will be able to:

to describe toxicities from common cancer therapies used to treat breast cancer, prostate cancer, and lung cancer, with some focus on endocrine therapies (for breast and prostate cancer);
identify which patients require cardiology involvement and post-therapy surveillance, and the optimal surveillance strategies. To describe strategies to reduce cardiovascular events in these patients; and
recognize the importance of collaboration between oncologists, cardiologists, and general practitioners to improve the cardiovascular health of cancer survivors.